[my country's recombinant protein new coronavirus vaccine phase I phase II clinical trial results released]

　　my country has approved a recombinant protein subunit new coronavirus vaccine for emergency use. The results of phase I and phase II clinical trials were recently published in the international medical journal "The Lancet · Infectious Diseases".

The results showed that the safety of the vaccine was good. 97% of the participants who received 3 doses of 25 micrograms vaccine produced neutralizing antibodies that can block the live virus, and the level of neutralizing antibodies exceeded the serum of recovered patients.

　　The vaccine was developed by the Institute of Microbiology of the Chinese Academy of Sciences in conjunction with Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd. It was evaluated and approved by relevant departments for emergency use on March 10 this year.

　　According to reports, a total of 950 healthy adults between the ages of 18 and 59 were recruited in the domestic two-phase clinical trials of the vaccine, using a randomized, double-blind, and placebo-controlled trial protocol.

The test evaluates the safety and immunogenicity of the vaccine, including adverse events and serious adverse events, antibody titers, neutralizing antibody titers, and seroconversion rate.

　　The results showed that no serious vaccine-related adverse events occurred.

After 2 doses of vaccine, 76% of people can produce neutralizing antibodies.

After 3 doses of vaccine, 97% of people can produce neutralizing antibodies.

　　The vaccine is currently undergoing international multi-center phase III clinical trials in Uzbekistan, Indonesia, Pakistan and Ecuador, and was approved for registration in Uzbekistan on March 1.

　　Recombinant protein subunit vaccines express and purify pathogen antigen proteins in engineered cells through genetic engineering, and then prepare them into vaccines.

Different from inactivated vaccines and adenovirus vector vaccines, this is a new coronavirus vaccine developed by a new technical route.

　　Up to now, my country has 4 new coronavirus vaccines on the market conditionally, and one new coronavirus vaccine has been approved for emergency use.

(Reporters Dong Ruifeng and Xu Haitao)